Baker Brothers Life Sciences LP, Director at BeiGene, Ltd. (BGNE), sold 1,074,034 shares at $186.50 ($201.9M) on 2024-12-09, disclosed to the SEC on 2024-12-10.
Open-market sale of $201.9M BGNE by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $186.50 | 83,036 | $15.5M | 7.7% |
| 2 | $186.50 | 916,964 | $171.0M | 84.7% |
| 3 | $208.01 | 3,074 | $639K | 0.3% |
| 4 | $208.01 | 3,074 | $639K | 0.3% |
| 5 | $208.01 | 33,943 | $7.1M | 3.5% |
| 6 | $208.01 | 33,943 |
| $7.1M |
| 3.5% |
| Total | $187.98 avg | 1,074,034 | $201.9M | 100% |
| Filing → |
| MDGL | BUY | 2023-11-21 | $22.1M | — | Filing → |
| BGNE | SELL | 2023-11-14 | $198.6M | — | Filing → |
| NLTX | BUY | 2023-08-17 | $2.9M | — | Filing → |